STOCK TITAN

Orgenesis Inc. - ORGS STOCK NEWS

Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.

Orgenesis Inc. (NASDAQ: ORGS) is a pioneering biotech company focused on unlocking the potential of cell and gene therapies (CGTs). Headquartered in White Plains, New York, Orgenesis specializes in autologous therapies, employing a closed and automated processing system designed for compliant production close to the patient, enhancing the efficiency of treatments at the point of care (POCare).

The company operates through two main segments: Octomera and Therapies. Octomera is the company's decentralized cell therapy platform, which has been fundamental in their approach to CGT production. Their decentralized model allows for the integration of academia, hospitals, and industry partners to expedite the commercialization of these therapies. This approach not only reduces costs but also improves patient outcomes by bringing processing services closer to the patient.

Despite industry challenges in 2023, Orgenesis remains steadfast in its mission. CEO Vered Caplan highlighted the growing demand for decentralized cell therapy solutions due to cost pressures and patient demand. Orgenesis has seen support from regulators like the FDA and EMEA, who are progressing guidelines for decentralized production. These advancements have solidified the company’s strategic advantage in handling the development and regulatory processes of their products.

On the financial front, Orgenesis has made significant strides. The recent appointment of Victor Miller as CFO has brought renewed focus on their financial strategy, leveraging their robust cell processing expertise to secure their position in the life sciences sector. Their collaboration with Metalmark has provided critical support, aiding in navigating the biotech industry's fluctuations.

Orgenesis is also at the forefront of developing therapeutic exosomes through their EXOFASTTRACK project. This project aims to accelerate the clinical evaluation of therapeutic exosomes, providing a scalable and cost-effective production process that can revolutionize the field of advanced therapy medicinal products (ATMPs).

Furthermore, Orgenesis has strengthened its infrastructure through a strategic partnership with Germfree. This collaboration focuses on advancing Orgenesis’ therapeutic programs and cell processing services, aiming to make CGTs more accessible and affordable globally. The partnership also includes marketing Orgenesis' decentralized Octomera service platform and its Mobile Processing Units and Labs (OMPULs™).

Orgenesis continues to innovate and expand its global footprint, committed to bringing life-saving therapies to market faster and more efficiently. Their decentralized approach and strategic collaborations position them as leaders in transforming how cell and gene therapies are developed and delivered.

For more information, please visit www.orgenesis.com.

Rhea-AI Summary

Orgenesis (NASDAQ: ORGS) announced positive results from a real-world study of its CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. The study showed complete response rates of 82% in adults and 93% in pediatric patients, with low incidence of severe Cytokine Release Syndrome (2% in adults, 6% in pediatrics).

ORG-101 utilizes a third-generation lentiviral vector with a proprietary CAR construct and decentralized onsite production, offering a potentially more affordable solution compared to traditional CAR-T therapies. Orgenesis is preparing to initiate a Phase 1/2 clinical multicenter study, starting in Greece.

Harley Street Healthcare Group plans to set up a Global Cancer Initiative through its joint venture with Orgenesis, aiming to democratize Advanced Therapies and support further clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
Rhea-AI Summary

Orgenesis (NASDAQ: ORGS) has formed a strategic partnership with Harley Street Healthcare Group (HSHG) to launch a global Longevity & Wellness Initiative. This alliance aims to drive innovation in wellness and longevity, supported by an investment commitment of up to $10 million over 3 years into both Orgenesis and a newly formed joint venture.

The partnership combines Orgenesis' expertise in cell and gene therapies with HSHG's innovative healthcare approach. This collaboration is expected to accelerate the development and accessibility of advanced therapies in the wellness and longevity sectors, potentially opening new markets and revenue streams for Orgenesis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

Orgenesis Inc. (NASDAQ: ORGS), a global biotech company focused on cell and gene therapies (CGT), provided a business update for Q2 2024. The company has acquired GMP-validated platforms for producing CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes. CEO Vered Caplan highlighted the integration of their robust cell therapy production capabilities with their wide range of therapies developed through partnerships. Orgenesis now offers hospitals and partners both services for their own development and products, as well as the opportunity to benefit from Orgenesis' proprietary therapies. The company plans to use the newly acquired platform to supply its own CAR-T cell products, aiming to provide a comprehensive solution for the industry, including hospitals and researchers worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.59%
Tags
Rhea-AI Summary

Orgenesis (NASDAQ: ORGS), a biotech company focused on cell and gene therapies (CGT), provided a business update for Q1 2024. The company accelerated the rollout of its decentralized POCare platform following a partnership with Germfree and reacquisition of full ownership of Octomera. This enhances their Orgenesis Mobile Processing Units and Labs (OMPULs) offering, aimed at delivering cost-effective, rapidly deployable CGT solutions. A strategic partnership with Germfree grants access to a global network, bolstering the company's go-to-market strategy. Orgenesis has secured over $50 million in potential future grant funding, and additional investments of $2.5 million were received. Furthermore, shareholders agreed to exchange $16 million of debt for 15.8 million shares of common stock, demonstrating strong support. Financial details are available on Orgenesis' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.27%
Tags
none
-
Rhea-AI Summary
Orgenesis Inc. provided a year-end business update, highlighting major transformations, such as acquiring full ownership of Octomera, securing a $2.3 million investment at a premium price, and entering into a strategic collaboration agreement. The company focuses on decentralized production for cell and gene therapies, aiming to reduce costs and expand production capacity. Despite industry challenges, Orgenesis remains optimistic about the future, leveraging grants and partnerships to advance its therapeutic pipeline and meet growing demand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform with Germfree, enhancing market expansion opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
partnership
Rhea-AI Summary
Orgenesis Inc. (ORGS) CEO, Vered Caplan, to present at Bioprocessing Summit Europe on overcoming conventional CGT processing challenges with POCare solutions. The conference aims to advance manufacturing and quality control of biological and genetic therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
conferences
-
Rhea-AI Summary
Orgenesis Inc. has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project, focusing on manufacturing therapeutic exosomes. The project aims to accelerate the development of multiple therapeutic exosomes for clinical evaluation, potentially reducing production costs and promoting accessibility to life-saving therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
Rhea-AI Summary
Orgenesis Inc. announced a private placement agreement with accredited investors for the sale of shares and warrants, expecting to raise around $2.3 million. The deal includes 2,272,719 shares of common stock and corresponding warrants at different exercise prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
none
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a €2.0 million grant from the Walloon Government in Belgium for AI monitoring of decentralized ATMP manufacturing. The project aims to enhance the production of advanced therapy medicinal products through AI-based approaches. The grant is part of a larger initiative with an €81 million budget over three years to drive technological innovation in the ATMP sector, creating jobs and fostering partnerships. Orgenesis plans to utilize the grant to accelerate the placement of a CAR-T dedicated facility in Belgium, making CAR-T therapies more affordable in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
AI

FAQ

What is the current stock price of Orgenesis (ORGS)?

The current stock price of Orgenesis (ORGS) is $0.595 as of September 16, 2024.

What is the market cap of Orgenesis (ORGS)?

The market cap of Orgenesis (ORGS) is approximately 27.9M.

What is Orgenesis Inc.'s primary focus?

Orgenesis Inc. focuses on unlocking the potential of cell and gene therapies, particularly through autologous therapies and a decentralized production approach.

Where is Orgenesis Inc. headquartered?

Orgenesis Inc. is headquartered in White Plains, New York, United States.

What are the main business segments of Orgenesis Inc.?

Orgenesis operates through two main segments: Octomera and Therapies.

What is the Octomera platform?

The Octomera platform represents Orgenesis' decentralized cell therapy model, bringing processing services closer to patients to enhance efficiency and reduce costs.

Who is the CEO of Orgenesis Inc.?

Vered Caplan is the CEO of Orgenesis Inc.

What strategic partnership did Orgenesis recently announce?

Orgenesis recently announced a strategic partnership with Germfree to advance their therapeutic programs and cell processing services.

How does Orgenesis contribute to the development of therapeutic exosomes?

Orgenesis is involved in the EXOFASTTRACK project, aimed at developing a scalable and cost-effective production process for therapeutic exosomes.

What is the significance of Orgenesis' decentralized approach?

Orgenesis' decentralized approach brings academia, hospitals, and industry together, reducing costs and improving patient outcomes by making essential therapies more accessible.

How has Orgenesis addressed the challenges in the biotech industry?

Orgenesis has adapted by focusing on decentralized cell therapy solutions, receiving support from regulators, and strengthening financial strategies through key appointments and collaborations.

Where can I find more information about Orgenesis?

More information about Orgenesis can be found on their official website at www.orgenesis.com.

Orgenesis Inc.

Nasdaq:ORGS

ORGS Rankings

ORGS Stock Data

27.92M
46.93M
21.52%
4.66%
0.76%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GERMANTOWN